As FDA responds to a spate of drug shortages, there is talk within the agency about treating the underlying failure of the pharmaceutical industry to adequately increase production capacity as a GMP issue, an FDA official told the Interphex conference in New York.
It’s a discussion that gives quality managers a reason to monitor utilization rates and advocate for sufficient plant capacity.